The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma

Journal of Urology

Volumn 166, Issue 3, 2001, Pages 1098-1105

  Duggan, Brian J ^a   Maxwell, Perry ^b   Kelly, John D ^b   Canning, Paul ^b   Anderson, Neil H ^b   Keane, Patrick F ^b   Johnston, Samuel R ^b   Williamson, Kate E ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Apoptosis; Bladder; Bladder neoplasms; Mitomycin; Oligonucleotides, antisense

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MITOMYCIN C; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BLADDER IRRIGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 0034880019     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65929-0     Document Type: Article

References (28)

1. Superficial bladder cancer: Progression and recurrence
2. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder
3. Apoptosis and cancer chemotherapy
4. Apoptosis and chemotherapy resistance
5. Bcl-2/bax expression and p53 gene status in human bladder cancer: Relationship to early recurrence with intravesical chemotherapy after resection
6. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer
7. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
8. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
9. Abnormal Bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer
10. Bcl-2 and p53 expressions in invasive bladder cancers
11. Apoptosis and its clinical significance for bladder cancer therapy
12. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
13. Pharmacokinetics of G3139 a phosphorothioate oligodeoxynucleotide anti-sense to bcl-2 following intravenous administration or continuous subcutaneous infusion to mice
14. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
15. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
16. Bcl-2 antisense therapy for cancer: The art of persuading tumour cells to commit suicide
17. Expression of Bcl-2 and bcl-X in bladder cancer
18. Incidence of apoptosis, cell proliferation and Bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression
19. Expression of apoptosis suppressing Bcl-2 protein in transitional cell bladder tumours
20. Variation of Bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: Overexpression and absence of variation in fibroadenomas
21. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques
22. Carcinoma in situ
23. Bacillus Calmette-Guerin immunotherapy for bladder cancer
24. Antisense therapy for lymphomas
25. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
26. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
27. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors